1. Introduction {#sec1-jcm-09-01398}
===============

Since warfarin was approved for use in 1954, it has been the mainstay of anticoagulant treatment for patients with atrial fibrillation, deep vein thrombosis and pulmonary embolism. However, the use of vitamin K antagonists (VKAs) has many limitations, such as the need to ensure proper anticoagulation control by regular monitoring and also many interactions with drugs and diet. As a result, 30--50% of patients are undertreated \[[@B1-jcm-09-01398],[@B2-jcm-09-01398],[@B3-jcm-09-01398],[@B4-jcm-09-01398]\]. In the last 10 years, the US Food and Drug Administration (FDA) has approved non-vitamin K antagonist oral anticoagulants (NOACs), long-awaited alternatives to the vitamin K antagonists that offer relative efficacy, safety and convenience. This new class of drugs includes dabigatran, rivaroxaban, apixaban and edoxaban. They have the convenience of fixed dosing with no need for laboratory monitoring or dietary discretion \[[@B5-jcm-09-01398],[@B6-jcm-09-01398],[@B7-jcm-09-01398],[@B8-jcm-09-01398],[@B9-jcm-09-01398],[@B10-jcm-09-01398],[@B11-jcm-09-01398]\]. But despite these apparent advantages, debate still remains regarding the gastrointestinal bleeding (GIB) risk \[[@B12-jcm-09-01398],[@B13-jcm-09-01398],[@B14-jcm-09-01398],[@B15-jcm-09-01398],[@B16-jcm-09-01398],[@B17-jcm-09-01398],[@B18-jcm-09-01398]\].

Compared with vitamin K antagonists or heparins, NOACs have rapid onset and offset of action, predictable pharmacodynamics, fewer food--drug and drug--drug interactions and can reversibly and directly inhibit a specific factor of the coagulation cascade \[[@B19-jcm-09-01398],[@B20-jcm-09-01398],[@B21-jcm-09-01398],[@B22-jcm-09-01398],[@B23-jcm-09-01398]\] ([Table 1](#jcm-09-01398-t001){ref-type="table"}).

Dabigatran targets thrombin and all xabans (apixaban, rivaroxaban, edoxaban) target factor Xa. The beginning of the anticoagulation effect is rapid and begins two hours following the first dose and is lost within 24 h after discontinuation of the drugs. Direct anti-Xa inhibitors are able to inhibit both free and prothrombinase-bound factor Xa, and may also be able to inhibit clot-associated factor Xa. It is important to mention that rivaroxaban does not react with antibodies implicated in heparin-induced thrombocytopenia \[[@B21-jcm-09-01398],[@B24-jcm-09-01398],[@B25-jcm-09-01398]\].

Dabigatran is a direct thrombin inhibitor, administered as a prodrug (dabigatran etexilate) and absorbed principally in the stomach and proximal small bowel as an inactive prodrug. Serum and hepatic esterases metabolize this inactive prodrug to the active drug. The bioavailability of the drug is low, approximately 3--7%, with the unabsorbed dabigatran being converted to active dabigatran in the distal bowel and then excreted in the feces \[[@B25-jcm-09-01398],[@B26-jcm-09-01398],[@B27-jcm-09-01398],[@B28-jcm-09-01398]\]. The majority of non-absorbed drug is excreted in the stool and the absorbed drug is mainly excreted unchanged by the kidneys. Compared with warfarin, which is not activated in the bowel, the active dabigatran in the distal bowel may promote gastrointestinal bleeding \[[@B25-jcm-09-01398],[@B26-jcm-09-01398]\]. There are also studies reporting that dabigatran is associated with esophagitis and gastric ulceration, suggesting that the drug may directly injure the gastrointestinal mucosa \[[@B29-jcm-09-01398]\]. Dabigatran may be given at a dose of 150 mg b.i.d or 110 mg b.i.d. The dose of 75 mg b.i.d can be administered in the presence of renal insufficiency (creatinine clearance (CrCl) \< 50 mL/min). The drug is contraindicated in patients with severe renal impairment (CrCl \< 30 mL/min) or advanced liver disease \[[@B30-jcm-09-01398],[@B31-jcm-09-01398],[@B32-jcm-09-01398],[@B33-jcm-09-01398],[@B34-jcm-09-01398]\].

Apixaban is a direct inhibitor of factor Xa and has a bioavailability of 50%. Almost 25% of the absorbed drug is excreted by the kidney with a half-life of around 12 h. Apixaban is administered at a dose of 5 mg b.i.d, and 2.5 mg b.i.d if patients have at least 2 of the following features: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or more \[[@B35-jcm-09-01398],[@B36-jcm-09-01398],[@B37-jcm-09-01398],[@B38-jcm-09-01398],[@B39-jcm-09-01398],[@B40-jcm-09-01398]\].

Rivaroxaban is also a direct factor Xa inhbitior, with a bioavailability of 66% and a half-life that ranges from 6 to 13 h \[[@B35-jcm-09-01398],[@B41-jcm-09-01398]\]. One-third of the absorbed drug is excreted by the kidney and two-thirds is metabolized by the liver into inactive forms. Rivaroxaban is administered at a dose of 20 mg daily, and 15 mg daily if the CrCl is \<50 mL/min. The drug is also contraindicated in severe renal impairment (CrCl \< 15 mL/min) and advanced liver disease \[[@B41-jcm-09-01398],[@B42-jcm-09-01398],[@B43-jcm-09-01398],[@B44-jcm-09-01398],[@B45-jcm-09-01398]\].

The anticoagulant effect can be local and/or systematic and the sites of gastrointestinal bleeding differ for individual NOACs. They have a systemic anticoagulant effect and also a local effect such as: incomplete absorption (topical anticoagulant effect), direct caustic effect (tartaric acid in dabigatran) or inhibition of mucosal healing \[[@B24-jcm-09-01398]\]. When compared with warfarin, aspirin or non-steroidal anti-inflammatory drugs, where upper gastrointestinal bleeding predominates \[[@B46-jcm-09-01398]\], in the RE-LY trial, lower GIB was found in 53% of dabigatran users. In this post hoc analysis of the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, comparing dabigatran to warfarin, Kolb et al. \[[@B24-jcm-09-01398]\] reviewed the cases of suspected GI bleeding. They collected data on the causative lesions and the site and acuity of bleeding within the bowel. They localized the bleeding in approximately two-thirds of the cases, and 47% of them were detected in the upper GI tract and 39% in the colon. It was interesting that the rate of bleeding in the upper GI tract was similar between the two doses of dabigatran studied (110 and 150 mg) as compared with warfarin, whereas lower GI bleeding (which included colonic, jejunal and ileal sources) was more frequent in patients treated with dabigatran as compared with warfarin (relative risk was 1.78 for dabigatran 110 mg and 2.23 for dabigatran 150 mg). This probably is related to the incomplete absorption of the active NOACs in the upper GI tract, which leads to an increased availability of dabigatran in the lower GI tract and also a topical effect on the mucosa leading to bleeding. This gastrointestinal bleeding risk is higher especially in the presence of preexisting lesions like angiodysplasias and erosions \[[@B47-jcm-09-01398],[@B48-jcm-09-01398],[@B49-jcm-09-01398],[@B50-jcm-09-01398]\]. A recent study published by Contaldo et al. evaluated the gastrointestinal bleeding caused by NOACs with videocapsule endoscopy. They enrolled 109 patients with iron deficiency anaemia, 18 of them taking oral anticoagulants, and demonstrated a trend in the association of oral anticoagulant use with small intestinal lesions at videocapsule endoscopy, despite a non-statistical significance (odds ratio (OR) = 3.38; 95% confidence interval (CI) 0.73--15.70; *P* = 0.10). This study highlights the usefulness of videocapsule endoscopy in providing clear information in patients with unexplained iron deficiency anaemia \[[@B51-jcm-09-01398]\].

Even if apixaban and rivaroxaban are both factor Xa inhibitors, with similar bioavailability, and are administered in active form, the risk of GIB differs in these two agents, and this may be related to the higher peak level of once-daily dosing of rivaroxaban than the twice-daily dosing of apixaban \[[@B52-jcm-09-01398],[@B53-jcm-09-01398]\]. The risk factors for NOACs-related gastrointestinal bleeding are summarized in [Table 2](#jcm-09-01398-t002){ref-type="table"}.

Considering the fact that debate still remains regarding the gastrointestinal bleeding risk for patients on anticoagulant therapy, either warfarin or NOACs, we aimed to highlight evidence from high-quality real world studies regarding the GIB risk for oral anticoagulants.

2. Experimental Section {#sec2-jcm-09-01398}
=======================

The availability of warfarin and these NOACs in real-world clinical practice allows opportunities for comparative effectiveness analyses, particularly of the gastrointestinal bleeding risk of these drugs when used outside the controlled setting of clinical trials. Because edoxaban was recently approved by the FDA in January 2015 and introduced to the market and because little real-world data are available, this study only focused on warfarin, dabigatran, rivaroxaban and apixaban. The main objective of our study was to compare the gastrointestinal bleeding risk among anticoagulated non-valvular atrial fibrillation patients on warfarin, dabigatran, rivaroxaban and apixaban. We compared GIB risk between each NOAC and warfarin, but also a direct pairwise comparison between individual NOACs.

Real-world studies (RWSs), by integrating data from electronic health records, claims databases and disease registries, could extend findings of RCTs to large patient populations in real-world practice. The idealized settings of a clinical trial may not adequately reflect the real-world safety profile of NOACs as they are prescribed in routine clinical practice \[[@B54-jcm-09-01398]\]. Therefore, RWSs are needed to clarify which anticoagulant would be the best choice for atrial fibrillation patients, to assess specifically the gastrointestinal safety profile.

In the present study, we summarized evidence from high-quality RWSs for a comprehensive and rigorous analysis on the GIB risk for NOACs. We followed the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines when performing this research. These studies were selected by performing a systematic search of MEDLINE, EMBASE and PUBMED, using the following items: gastrointestinal bleeding risk, GIB, dabigatran, rivaroxaban, apixaban, warfarin, real-world studies, atrial fibrillation. We included in the research only high-quality real-world studies that fulfilled the following criteria: (1) reported major gastrointestinal bleeding events in patients given NOACs or warfarin; (2) available data on clinical events; (3) adjusted hazard ratios between each NOAC versus warfarin and from direct pairwise comparison of different NOACs for major gastrointestinal bleeding; (4) studies coordinated by independent research groups, published between 01 January 2017 and 31 December 2019. Considering that funding bias may be a form of publication bias, a phenomenon that is also recognized and studied by the researchers, we preferred to include only real-world data that were not sponsored by pharmaceutical companies. We excluded (1) animal-based studies; (2) non-English-based studies; (3) abstract, editorials, case reports and reviews ([Figure 1](#jcm-09-01398-f001){ref-type="fig"}).

Of 286 records screened, we included data from 11 high-quality real-world studies that reported major gastrointestinal bleeding events in patients given NOACs or vitamin K antagonists ([Table 3](#jcm-09-01398-t003){ref-type="table"}).

3. Results {#sec3-jcm-09-01398}
==========

3.1. Characteristics of Patients Included in the Studies {#sec3dot1-jcm-09-01398}
--------------------------------------------------------

The primary outcome was major gastrointestinal bleeding, according to International Society on Thrombosis and Hemostasis criteria \[[@B64-jcm-09-01398]\]. Bleeding was detected by upper endoscopy or colonoscopy, depending on the patient's symptoms and personal pathological background. Data extracted from these studies included baseline characteristics, patient demographics, co-morbidities, CHA2DS2-VASC score, HAS-BLED score, pharmacologic risk factors (antiplatelet agents, non-steroidal anti-inflammatory drugs) for gastrointestinal bleeding and also data on major GI bleeding for patients with NOACs and vitamin K antagonists. After propensity-score matching, cohorts were closely balanced for all covariates, standardized differences of all baseline characteristics were \<10% in all the studies, demonstrating similarity of comparators with regard to the important socio-demographic, co-morbidity and pharmacological risk factors ([Table 4](#jcm-09-01398-t004){ref-type="table"}).

From all of the eleven studies, five of them evaluated the gastrointestinal bleeding risk by comparing each NOAC (dabigatran, rivaroxaban and apixaban) with warfarin, three by direct pairwise comparison of different NOACs and the other three by comparing each NOAC with warfarin and with each other NOAC.

3.2. Gastrointestinal Bleeding Risk Comparing Each NOAC with Warfarin {#sec3dot2-jcm-09-01398}
---------------------------------------------------------------------

When comparing NOACs with warfarin, we found that in most studies the risk of major gastrointestinal bleeding, which accounted for more than 80% of major extracranial bleeding, was increased with dabigatran and rivaroxaban and decreased with apixaban, compared with warfarin. The lowest risk of gastrointestinal bleeding was with apixaban compared with warfarin (HR for gastrointestinal bleeding for apixaban ranged between 0.45 (95% CI 0.34 to 0.59) and 1.13 (95% CI 0.79 to 1.63)). Dabigatran was associated with lower or no significant difference in the risk of gastrointestinal bleeding (HR for dabigatran ranged between 0.58 (95% CI 0.47 to 0.71) and 1.43 (95% CI 1.07 to 1.90)) compared to warfarin use. Rivaroxaban had similar or even higher risk of gastrointestinal bleeding compared with warfarin (HR for rivaroxaban ranged between 1.00 (95% CI 0.87 to 1.16) and 1.38 (95% CI 1.12 to 1.54)) ([Table 5](#jcm-09-01398-t005){ref-type="table"}).

It is surprising that the ranges of hazard ratios are so variable between the included studies, especially when comparing gastrointestinal bleeding risk of apixaban vs. warfarin (the ranges being between 0.45 to 1.13). The higher risk for gastrointestinal bleeding of each NOAC versus warfarin encountered during the first year in the study published by Forslund et al. \[[@B56-jcm-09-01398]\] might be related to depletion of susceptibles, the imposibility of quantifying some factors, such as biological age or severity of the co-morbidities, and also the non-excluding design of the study, which included all new users of oral anticoagulants from primary health care, hospital based in- and outpatient care or specialized ambulatory care. Subgroup analyses highlighted similar outcomes with warfarin and NOAC treatment in high-risk patients aged 80 and above, and in patients with prior severe bleeds.

3.3. Gastrointestinal Bleeding Risk by Direct Pairwise Comparison of Different NOACs {#sec3dot3-jcm-09-01398}
------------------------------------------------------------------------------------

Gastrointestinal bleeding occurred in all of the studies more frequently in patients given rivaroxaban than dabigatran (HR for rivaroxaban ranged between 1.15 (95% CI 0.99 to 1.36) and 1.35 (95% CI 0.91 to 2.00)). Apixaban was associated with a lower risk of GI bleeding than dabigatran (HR ranged between 0.39 (95% CI 0.27 to 0.58) and 0.95 (95% CI 0.65 to 1.18)) or rivaroxaban (HR ranged between 0.33 (95% CI 0.22 to 0.49) and 0.82 (95% CI 0.62 to 1.08)). We found that in all of the studies, apixaban had the most favorable GI safety profile and rivaroxaban the least favorable ([Table 6](#jcm-09-01398-t006){ref-type="table"}).

4. Discussion {#sec4-jcm-09-01398}
=============

This study involves all available evidence from high-quality RWSs that were not supported by pharmaceutical companies for a comprehensive and rigorous analysis on the GIB risk for NOACs. The results of our study confirm a low or a similar risk for major GIB between patients receiving apixaban or dabigatran compared with warfarin, and apixaban appears to be associated with the lowest risk of GIB. In most of the studies included in our research, apixaban was associated with a significantly lower risk of gastrointestinal bleeding compared with warfarin. In a direct comparison of the gastrointestinal safety of the NOACs, apixaban appears to be associated with lower risk of gastrointestinal bleeding, whereas rivaroxaban is associated with higher risk of major gastrointestinal bleeding. The once-daily dosing of rivaroxaban and twice-daily administration of dabigatran and apixaban might also explain the higher risk of major bleeding in rivaroxaban, given its higher peak in plasma concentrations \[[@B65-jcm-09-01398],[@B66-jcm-09-01398],[@B67-jcm-09-01398],[@B68-jcm-09-01398]\].

The possibility of a different bleeding site according to the type of molecule was discussed in only one study from the selected articles. Thus, in the study published by Vinogradova et al., it was observed that rivaroxaban was associated with higher risk compared with apixaban of a gastrointestinal and upper gastrointestinal bleed, in patients with atrial fibrillation. In those without atrial fibrillation, apixaban was associated with a lower risk of a gastrointestinal and upper gastrointestinal bleed compared with warfarin. Dabigatran and rivaroxaban were associated with a higher risk of a gastrointestinal bleed compared with apixaban, and rivaroxaban was also associated with a higher risk of an upper gastrointestinal bleed \[[@B62-jcm-09-01398]\].

Up to now, there have been systematic reviews and metaanalyses conducted to assess the gastrointestinal risk of NOACs, but from our knowledge, there is no review that has included only real world studies that were not supported by pharmaceutical companies.

Among different NOACs, it is difficult to conclude which drug has the lowest gastrointestinal bleeding risk as there are no direct head-to-head comparisons in randomized clinical trials (RCTs) and because patient characteristics are different across studies. Up to now, several systematic reviews and metaanalyses have been conducted to assess the GIB risk of NOACs in randomized clinical trials. One of the earliest meta-analyses \[[@B69-jcm-09-01398]\], which included 17 RCTs with a total of 75,081 patients who received either a NOAC or standard care (either low-molecular-weight heparin, vitamin K antagonist, antiplatelet therapy or placebo), demonstrated a 1.5% GIB event, with 89% being major GIB (defined as GIB leading to a decrease in hemoglobin ≥ 2 g/dl within 24 h, a transfusion of ≥ 2 units of packed red cells, necessitating intervention including surgery, or fatal bleeding). Holster et al. also demonstrated that there was an increased risk of GIB among NOAC users compared with standard care and that among different NOACs, dabigatran and rivaroxaban were associated with a higher risk of GIB (OR 1.58 and 1.48, respectively) \[[@B69-jcm-09-01398]\].

In a recent systematic review and meta-analysis of data from randomized controlled trials and real-world studies, Gu et al. \[[@B70-jcm-09-01398]\] evaluated the risk of major gastrointestinal bleeding in patients with NOACs compared with conventional treatment and confirmed that there is no significant difference between these two groups. They analyzed data from 43 randomized controlled trials (183,752 patients) and 41 real-world studies (1,879,428 patients). The pooled major rates of GIB for patients on NOACs (1.19%) vs conventional treatment (0.92%) did not differ significantly (HR from real-world studies, 1.02; 95% CI, 0.94--1.10; P interaction = 0.52). Rivaroxaban, but not other NOACs, was associated with an increased risk of major GIB (HR from real-world studies, 1.14; 95% CI, 1.04--1.23; P interaction = 0.06). Rivaroxaban users had a 39% increase in risk for major GIB. Analyses of subgroups, such as patients with different indications, dosage, or follow-up time, did not significantly affect results.

In another systematic review and meta-analysis, Li et al. \[[@B71-jcm-09-01398]\] summarized the evidence of observational studies for direct comparative safety amongst NOACs in patients with atrial fibrillation. They included fifteen studies for qualitative synthesis and twelve studies for meta-analyses. Rivaroxaban was associated with a significantly higher risk of major bleeding, in comparison with apixaban (HR = 1.71, 95% CI 1.51--1.94; evidence quality: low). Compared with dabigatran, apixaban was associated with lower risk of major bleeding (HR = 0.80, 95% CI 0.68--0.95; evidence quality: low). Apixaban was associated with a lower risk of major bleeding when compared with dabigatran or rivaroxaban, so it was found to have the most favorable safety profile amongst the three NOACs.

The major strength of this study was to reassess the risk for major GIB of NOACs by comparing the results from high-quality RWSs that were not supported by pharmaceutical companies. Certainly there are inherent limitations in this study. First, we included only 11 studies that met the criteria, which may reduce the statistical power. Second, all included studies reported major GIB events according to the International Society on Thrombosis and Hemostasis criteria, but it is not possible to evaluate whether small variations may have an impact on the results obtained. Another weakness of our study is that we did not perform a meta-analysis and, consequently, there are not any pooled estimates of hazard or risk ratios. In addition, we did not have the resources to review non-English articles, but we are confident that this study covered the majority of high-quality RWSs identified in a comprehensive search of broad databases.

5. Conclusions {#sec5-jcm-09-01398}
==============

The results of our study from real-world studies confirm a low or a similar risk for major gastrointestinal bleeding between patients receiving NOACs compared with conventional treatment with warfarin. In a direct comparison of the gastrointestinal safety of the NOACs, apixaban appears to be associated with a lower risk of gastrointestinal bleeding, whereas rivaroxaban is associated with a higher risk of major gastrointestinal bleeding. Our findings may provide some decision-making support for physicians regarding their selection of oral anticoagulant treatment based on risk for major gastrointestinal bleeding in patients with AF.
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jcm-09-01398-t001_Table 1

###### 

Indications and dosing of NOACs in Europe.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Indication                                                                                                                                                      Dabigatran                                                                     Apixaban                                  Rivaroxaban
  --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ----------------------------------------- -------------------------------------------
  Non-valvular atrial fibrillation                                                                                                                                150 mg b.i.d                                                                   5 mg b.i.d                                20 mg daily

  110 mg b.i.d if age ≥ 80 years (may consider 110 mg b.i.d also if increased risk of bleeding)                                                                   2.5 mg b.i.d if CrCl 15--29 mL/min OR two out of the following:\               \-                                        
                                                                                                                                                                  age ≥ 80 years, BW ≤ 60 kg,\                                                                                             
                                                                                                                                                                  Cr ≥ 1.5 mg/dL                                                                                                           

  Avoid if CrCl \< 30 mL/min                                                                                                                                      Avoid if CrCl \< 15 mL/min                                                     Avoid if CrCl \< 15 mL/min                

  Treatment and prevention of recurrent\                                                                                                                          150 mg b.i.d after 5 days of initial therapy with a parenteral anticoagulant   10 mg b.i.d for 1 week, then 5 mg b.i.d   15 mg b.i.d for 3 weeks, then 20 mg daily
  deep vein thrombosis/\                                                                                                                                                                                                                                                                   
  pulmonary embolism                                                                                                                                                                                                                                                                       

  110 mg b.i.d after 5 days of initial therapy with a parenteral anticoagulant if age ≥ 80 years (may consider 110 mg b.i.d also if increased risk of bleeding)   \-                                                                             \-                                        

  Avoid if CrCl \< 30 mL/min                                                                                                                                      Avoid if CrCl \< 15 mL/min                                                     Avoid if CrCl \< 15 mL/min                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NOACs: non-vitamin K antagonist oral anticoagulants; CrCl: Creatinine clearance; BW: Body weight; Cr: Creatinine; b.i.d: Twice a day.

jcm-09-01398-t002_Table 2

###### 

Factors associated with NOACs-related gastrointestinal bleeding.

  ----------------------------------------------------------------------------------------------------------------------
  **Risk Factors**

  1\. Higher dose of dabigatran: a dose of 150 mg b.i.d\
  2. Concomitant use of ulcerogenic agents like antiplatelet agents, non-steroidal anti-inflammatory drugs or steroid\
  3. Older age: ≥75 years\
  4. Renal impairment with a creatinine clearance \<50 mL/min\
  5. Prior history of peptic ulcers or GIB\
  6. Helicobacter pylori infection\
  7. Pre-existing GI tract lesions such as: diverticulosis, angiodysplasias\
  8. Ethnicity: western population\
  9. HAS-BLED score ≥3

  **Protective Factors**

  Gastroprotective agents: proton pump inhibitors or histamine H2-receptor antagonists
  ----------------------------------------------------------------------------------------------------------------------

HAS-BLED: a scoring system developed to assess 1-year risk of major bleeding in patients taking anticoagulants with atrial fibrillation. The score is between 0 and 9, based on seven parameters: hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, labile INR, elderly (\>65 years), drug/alcohol concomitantly (1 point each).

jcm-09-01398-t003_Table 3

###### 

Real-world studies that analyzed NOACs-related gastrointestinal bleeding.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                        Country   Obser-Vation Period              Oral Anticoagu-Lants Analyzed                  Methodology                                                                                                                                                                       Population                                                                                                                                                                          Endpoint
  -------------------------------------------- --------- -------------------------------- ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------
  Abraham et al. \[[@B54-jcm-09-01398]\]       USA       October 2010 to February 2015    Apixaban, dabigatran or rivaroxaban            Retrospective cohort study based on medical and pharmacy claims data from OptumLabs Data Warehouse using PSM                                                                      43,303 adults diagnosed with NVAF who had an indexprescription for apixaban, dabigatran, or rivaroxaban                                                                             Bleeding

  Adeboyeje et al. \[[@B55-jcm-09-01398]\]     USA       November 2010 to February 2015   Apixaban, dabigatran, rivaroxaban, warfarin    Retrospective cohort study based on data from a commercially insured population in the U.S.                                                                                       44,057 patients diagnosed with NAVF, who used warfarin (23,431), dabigatran (8539), apixaban (3689) and rivaroxaban (8398)                                                          Bleeding

  Andersson et al. \[[@B30-jcm-09-01398]\]     Denmark   July 2013 to March 2016          Apixaban, dabigatran or rivaroxaban            Retrospective cohort study based on nationwide registers                                                                                                                          12,638 NVAF patients, propensity scores in a 1:1 ration comparing (apixaban vs. dabigatran = 6470; apixaban vs. rivaroxaban = 7352; rivaroxaban vs. dabigatran = 5440 patients)     Effective-ness + bleeding

  Forslund et al. \[[@B56-jcm-09-01398]\]      Sweden    January 2012 to December 2015    Apixaban, dabigatran, rivaroxaban, warfarin    Population-based retrospective cohort study based on data from the Stockholm Region administrative health data register containing healthcare utilization and prescription data   22,198 adults with NVAF who were naive for either warfarin or one of the following NOACs: apixaban, dabigatran, or rivaroxaban during the study period.                             Effective-ness + bleeding

  Graham et al. \[[@B57-jcm-09-01398]\]        USA       October 2010 to September 2015   Apixaban, dabigatran, rivaroxaban, warfarin    Retrospective new-users cohort study based on data from Medicare beneficiaries                                                                                                    183,318 warfarin, 86,198 dabigatran, 106,389 rivaroxaban and 73,039 apixaban users                                                                                                  Effective-ness + bleeding

  Hernandez et al. \[[@B58-jcm-09-01398]\]     USA       January 2013 to December 2014    Apixaban, dabigatran, rivaroxaban, warfarin    Retrospective database analysis from a random sample of Medicare beneficiaries                                                                                                    41,366 adults with NVAF who were naive for either warfarin or one of the following NOACs: apixaban, dabigatran or rivaroxaban during the study period.                              Effective-ness + bleeding

  Larsen et al. \[[@B59-jcm-09-01398]\]        Denmark   August 2011 to October 2015      Warfarin, apixaban, dabigatran, rivaroxaban\   Retrospective database analysis using propensity score weighting (inverse probability of treatment weighting)                                                                     61,678 NVAF patients, naive to OAC, first time on DOAC or warfarin                                                                                                                  Effective-ness + bleeding
                                                                                          (only standard dose)                                                                                                                                                                                                                                                                                                                                                                                                 

  Nielsen et al. \[[@B60-jcm-09-01398]\]       Denmark   August 2011 to February 2016     Warfarin, apixaban, dabigatran, rivaroxaban\   Retrospective analysis using propensity score weighting (inverse probability of treatment weighting)                                                                              55,644 NVAF patients, naïve to OAC, first time on DOAC or warfarin, all restricted to reduced dose                                                                                  Effective-ness + bleeding\
                                                                                          (only reduced dose)                                                                                                                                                                                                                                                                                                                                                                                                  

  Noseworthy et al. \[[@B61-jcm-09-01398]\]    USA       October 2010 to June 2015        Rivaroxaban, dabigatran, apixaban              Retrospective analysis using administrative claims, using PSM and Cox proportional hazards regression                                                                             57,788 NVAF patients, including patients with prior warfarin exposure. Apixaban used as reference category                                                                          Effective-ness + bleeding

  Vinogradova et al. \[[@B62-jcm-09-01398]\]   UK        January 2011 to October 2016     Warfarin, apixaban, dabigatran, rivaroxaban    Prospective open cohort study using two primary care databases representative of the national population                                                                          132,231 warfarin, 7744 dabigatran, 37,863 rivaroxaban and 18,223 apixaban users, subgrouped into 103,270 patients with atrial fibrillation and 92,791 without atrial fibrillation   Bleeding

  Yao et al. \[[@B63-jcm-09-01398]\]           USA       October 2010 to\                 Warfarin, apixaban, dabigatran, rivaroxaban    Retrospective database analyses using PSM                                                                                                                                         125,243 NVAF patients, three 1:1 PSM cohorts (apixaban = 15,390; dabigatran = 28,614; rivaroxaban = 32,350)                                                                         Effective-ness + bleeding
                                                         June 2015                                                                                                                                                                                                                                                                                                                                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NOACs: non-vitamin K antagonist oral anticoagulants; NVAF: nonvalvular atrial fibrillation; OAC: oral anticoagulant; DOAC: direct oral anticoagulant; PSM: propensity score matching.

jcm-09-01398-t004_Table 4

###### 

Baseline characteristics of patients included in the studies.

  ---------------------------------------------------------------------------------------------------------------------------
                                                         Dabigatran      Rivaroxaban   Apixaban      Warfarin      Maximum\
                                                                                                                   SMD
  ------------------------------------------------------ --------------- ------------- ------------- ------------- ----------
  **Study Abraham et al. \[[@B54-jcm-09-01398]\]**                                                                 

  Age group (mean)                                       68.8 (11.4)     70.6 (11.4)   72.3 (11.1)   NA            \-

  Male                                                   60.5%           57.1%         54%           NA            \-

  CHA2DS2-VASC (mean)                                    3.6 (1.9)       3.8 (1.9)     4.0 (1.9)     NA            \-

  HAS-BLED (mean)                                        2.2 (1.2)       2.4 (1.2)     2.4 (1.2)     NA            \-

  Antiplatelet or non-steroidal\                         10.7%           12.1%         12.3%         NA            \-
  anti-inflammatory drugs                                                                                          

  **Study Adeboyeje et al. \[[@B55-jcm-09-01398]\]**                                                               

  Age group (mean)                                       70 (12.3)       70 (12.3)     70 (12.6)     70 (12.2)     0.01

  Male                                                   58.9%           58.7%         59.5%         59.1%         0.01

  CHA2DS2-VASC (mean)                                    3.3 (1.9)       3.3 (1.9)     3.3 (1.9)     3.3 (1.8)     0.01

  HAS-BLED (mean)                                        2.1 (1.4)       2.1 (1.4)     2.1 (1.4)     2.1 (1.4)     0.01

  Antiplatelet or non-steroidal\                         19.9%           20.5%         20.2%         20.2%         0.01
  anti-inflammatory drugs                                                                                          

  **Study Andersson et al. \[[@B30-jcm-09-01398]\]**                                                               

  Age group (mean)                                       65.7 (7.3)      72.0 (9.8)    71.9 (9.1)    NA            \-

  Male                                                   64%             56%           63%           NA            \-

  CHA2DS2-VASC                                           \-              \-            \-            NA            \-

  HAS-BLED                                               \-              \-            \-            NA            \-

  Antiplatelet or non-steroidal\                         59.8%           61.8%         57.8%         NA            \-
  anti-inflammatory drugs                                                                                          

  **Study Forslund et al. \[[@B56-jcm-09-01398]\]**                                                                

  Age group (mean)                                       69.9 (11.3)     74.0 (10.3)   75.0 (10.8)   74.1 (11.0)   \-

  Male                                                   60%             54.6%         54.6%         55.4%         \-

  CHA2DS2-VASC (mean)                                    3\. 01 (1.89)   3.59 (1.88)   3.69 (1.9)    3.68 (1.91)   \-

  HAS-BLED                                               \-              \-            \-            \-            \-

  Antiplatelet drugs                                     46.73%          55.74%        47.73%        54.96%        \-

  **Study Graham et al. \[[@B57-jcm-09-01398]\]**                                                                  

  Age group (mean)                                       75.5            74.9          75.2          75.8          0.15

  Male                                                   52.4%           53.9%         52.2%         52%           0.04

  CHA2DS2-VASC (≥2)                                      96.7%           96.6%         97.4%         97.1%         0.04

  HAS-BLED (≥3)                                          44.7%           43.7%         47.8%         45.8%         0.03

  Antiplatelet or non-steroidal\                         28.3%           28.2%         29.5%         27.2%         0.04
  anti-inflammatory drugs                                                                                          

  **Study Hernandez et al. \[[@B58-jcm-09-01398]\]**                                                               

  Age group (mean)                                       74.9 (8.7)      76.4 (8.6)    77.4 (8.6)    76.0 (10.3)   \<0.001

  Male                                                   47.0%           43.7%         42.5%         43.1%         \<0.001

  CHA2DS2-VASC (mean)                                    4.26 (1.74)     4.55 (1.78)   4.68 (1.73)   4.8 (1.82)    \<0.001

  HAS-BLED (mean)                                        3.49 (0.93)     3.65 (0.95)   3.71 (0.93)   3.71 (1.0)    \<0.001

  Antiplatelet or non-steroidal\                         22.5%           25.2%         25.0%         21.3%         \<0.001
  anti-inflammatory drugs                                                                                          

  **Study Larsen et al. \[[@B59-jcm-09-01398]\]**                                                                  

  Age group (mean)                                       67.6 (5.6)      71.8 (7.1)    71.3 (5.9)    72.4 (7.4)    0.02

  Male                                                   66.1%           57.9%         60.3%         58.8%         0.02

  CHA2DS2-VASC (mean)                                    2.2 (1.4)       2.8 (1.6)     2.8 (1.6)     2.8 (1.7)     0.02

  HAS-BLED (mean)                                        2.0 (1.1)       2.2 (1.2)     2.3 (1.2)     2.2 (1.2)     0.01

  Aspirin or non-steroidal\                              62.7%           60.4%         60.2%         66.3%         0.01
  anti-inflammatory drugs                                                                                          

  **Study Nielsen et al. \[[@B60-jcm-09-01398]\]**                                                                 

  Age group (mean)                                       79.9 (9.0)      77.9 (13.5)   83.9 (8.2)    71.0 (12.6)   0.09

  Male                                                   46.3%           46.8%         39.4%         59.6%         0.03

  CHA2DS2-VASC (mean)                                    3.8 (1.5)       3.6 (1.8)     4.3 (1.5)     3.0 (1.7)     0.04

  HAS-BLED (mean)                                        2.7 (1.0)       2.5 (1.2)     2.8 (1.1)     2.4 (1.2)     0.06

  Aspirin or non-steroidal\                              74.8%           66.2%         66.7%         70.2%         0.03
  anti-inflammatory drugs                                                                                          

  **Study Noseworthy et al. \[[@B61-jcm-09-01398]\]**                                                              

  Age group (median)                                     71 (62--78)     73 (65--81)   73 (65--81)   NA            \-

  Male                                                   58.9%           54.4%         54.1%         NA            \-

  CHA2DS2-VASC (median)                                  4 (2--5)        4 (3--5)      4 (3--5)      NA            \-

  HAS-BLED (median)                                      2 (1--3)        2 (2--3)      2 (2--3)      NA            \-

  Antiplatelet or non-steroidal\                         11.1%           11.7%         12.2%         NA            \-
  anti-inflammatory drugs                                                                                          

  **Study Vinogradova et al. \[[@B62-jcm-09-01398]\]**                                                             

  Age group (mean)                                       74.5 (10.7)     75.8 (10.8)   76.5 (10.9)   74.8 (10.4)   \-

  Male                                                   59.5%           54.3%         53.4%         55.6%         \-

  CHA2DS2-VASC                                           \-              \-            \-            \-            \-

  HAS-BLED                                               \-              \-            \-            \-            \-

  Antiplatelet or non-steroidal\                         39.6%           32.3%         31.3%         41.8%         \-
  anti-inflammatory drugs                                                                                          

  **Study Yao et al. \[[@B63-jcm-09-01398]\]**                                                                     

  Age group (median)                                     70 (62--78)     72 (64--80)   73 (66--81)   73 (66--81)   \-

  Male                                                   61.3%           57.8%         53.1%         53.2%         \-

  CHA2DS2-VASC (median)                                  3 (2--5)        4 (2--5)      4 (3--5)      4 (3--5)      \-

  HAS-BLED (median)                                      2 (1--3)        2 (2--3)      2 (2--3)      2 (2--3)      \-

  Antiplatelet or non-steroidal\                         10.3%           11.6%         12.1%         12.5%         \-
  anti-inflammatory drugs                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------

SMD---standardized mean difference; CHA2DS2-VASC score---assigns points for the presence of congestive heart failure, hypertension, age 65--74 years and age ≥75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, and female sex; HAS-BLED score---assigns points for the presence of hypertension, abnormal renal or liver function, stroke, bleeding history, labile INR, age ≥65 years, and antiplatelet drug or alcohol use; NA---not applicable.

jcm-09-01398-t005_Table 5

###### 

Adjusted hazard ratios with 95% confidence intervals from comparisons of each NOAC versus warfarin for major gastrointestinal bleeding.

  Study                                        Dabigatran vs. Warfarin   Rivaroxaban vs. Warfarin   Apixaban vs. Warfarin
  -------------------------------------------- ------------------------- -------------------------- -----------------------
  Forslund et al. \[[@B56-jcm-09-01398]\]      1.43 (1.07--1.9)          1.28 (0.90--1.80)          1.13 (0.79--1.63)
  Larsen et al. \[[@B59-jcm-09-01398]\]        0.58 (0.47--0.71)         1.06 (0.91--1.23)          0.61 (0.49--0.75)
  Nielsen et al. \[[@B60-jcm-09-01398]\]       0.87 (0.75--1.01)         1.17 (0.94--1.45)          1.04 (0.76--1.43)
  Vinogradova et al. \[[@B62-jcm-09-01398]\]   1.08 (0.83--1.41)         1.21 (1.01--1.45)          0.76 (0.58--0.99)
  Yao et al. \[[@B63-jcm-09-01398]\]           0.79 (0.67--0.94)         1.04 (0.90--1.20)          0.45 (0.34--0.59)
  Graham et al. \[[@B57-jcm-09-01398]\]        1.04 (0.9--1.21)          1.38 (1.12--1.54)          0.51 (0.42--0.61)
  Adeboyeje et al. \[[@B55-jcm-09-01398]\]     1.17 (1.04--1.32)         1.00 (0.87--1.16)          0.82 (0.63--1.06)
  Hernandez et al. \[[@B58-jcm-09-01398]\]     0.95 (0.75--1.19)         1.35 (1.20--1.52)          0.72 (0.57--0.90)

jcm-09-01398-t006_Table 6

###### 

Adjusted hazard ratios with 95% confidence intervals from direct pairwise comparison of different NOACs for major gastrointestinal bleeding.

  Study                                       Rivaroxaban vs. Dabigatran   Apixaban vs. Dabigatran   Apixaban vs. Rivaroxaban
  ------------------------------------------- ---------------------------- ------------------------- --------------------------
  Andersson et al. \[[@B30-jcm-09-01398]\]    1.35 (0.91--2.00)            0.94 (0.62--1.41)         0.88 (0.64--1.22)
  Abraham et al. \[[@B54-jcm-09-01398]\]      1.20 (1.00--1.45)            0.39 (0.27--0.58)         0.33 (0.22--0.49)
  Noseworthy et al. \[[@B61-jcm-09-01398]\]   1.30 (1.10--1.53)            0.50 (0.36--0.70)         0.39 (0.28--0.54)
  Graham et al. \[[@B57-jcm-09-01398]\]       1.32 (1.21--1.45)            0.56 (0.32--0.74)         0.38 (0.27--0.59)
  Adeboyeje et al. \[[@B55-jcm-09-01398]\]    1.15 (0.99--1.36)            0.95 (0.65--1.18)         0.82 (0.62--1.08)
  Hernandez et al. \[[@B58-jcm-09-01398]\]    1.25 (1.06--1.39)            0.76 (0.56--1.03)         0.53 (0.42--0.68)
